Fig. 4From: Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancerOverall survival in patients of the PETACC3 study according to SLFN11 levels and MSI status. a Overall survival in the 268 patients treated with LV5-FU2 regimen. b Overall survival in the 285 patients treated with FOLFIRI regimenBack to article page